{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T05:10:19Z","timestamp":1697433019310},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6125,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1093\/annonc\/mdg150","type":"journal-article","created":{"date-parts":[[2003,3,20]],"date-time":"2003-03-20T23:19:48Z","timestamp":1048202388000},"page":"574-579","source":"Crossref","is-referenced-by-count":18,"title":["Activity of raltitrexed and gemcitabine in advanced pancreatic cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"E.","family":"Kralidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Friess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.W.","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.","family":"Borner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg150_bb0010","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/bjc.1996.18","article-title":"Phase II study of gemcitabine in patients with advanced pancreatic cancer","volume":"73","author":"Carmichael","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg150_bb0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.1999.17.2.585","article-title":"Phase I\u2013II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer","volume":"17","author":"Hidalgo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000055295","article-title":"Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer","volume":"60","author":"Rauch","year":"2001","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdg150_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1023\/A:1008270916325","article-title":"The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)","volume":"9","author":"Borner","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0035","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group","volume":"16","author":"Cocconi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00873144","article-title":"Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer","volume":"13","author":"Pazdur","year":"1996","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdg150_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1093\/annonc\/mdg150_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdg150_bb0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.bjc.6690375","article-title":"Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan","volume":"80","author":"Okada","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg150_bb0060","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1200\/JCO.1997.15.6.2414","article-title":"Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study","volume":"15","author":"Whitehead","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0065","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0959-8049(00)00072-1","article-title":"A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma","volume":"36","author":"Rougier","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdg150_bb0070","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00001813-199606000-00006","article-title":"A phase II trial of topotecan in patients with previously untreated pancreatic cancer","volume":"7","author":"O\u2019Reilly","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdg150_bb0075","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0080","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1200\/JCO.20.6.1512","article-title":"Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study","volume":"20","author":"Louvet","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00001813-200009000-00004","article-title":"Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and\/or metastatic pancreatic cancer","volume":"11","author":"Brodowicz","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdg150_bb0090","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1023\/A:1026595525977","article-title":"Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer","volume":"11","author":"Heinemann","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.10323","article-title":"Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and\/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell\u2019Italia Meridionale","volume":"94","author":"Colucci","year":"2002","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdg150_bb0100","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1572-0241.1999.01018.x","article-title":"Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials","volume":"94","author":"Cubiella","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1093\/annonc\/mdg150_bb0105","first-page":"125a","article-title":"Docetaxel\/gemcitabine or docetaxel\/cisplatin in advanced pancreatic carcinoma a randomized phase II study of the EORTC-GI group","volume":"21","author":"Lutz","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0110","first-page":"125a","article-title":"Clinical outcome in patients with advanced pancreatic cancer treated with pemetrexed\/gemcitabine","volume":"21","author":"Kindler","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0115","first-page":"126a","article-title":"Oxaliplatin and gemcitabine for patients with pancreatic adenocarcinoma a NCCTG phase II study","volume":"21","author":"Alberts","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0120","first-page":"267a","article-title":"Combining gemcitabine and capecitabine in advanced pancreatic cancer","volume":"19","author":"Herrmann","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0125","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.20.2.582","article-title":"Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg150_bb0130","first-page":"126a","article-title":"Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma","volume":"21","author":"Scheithauer","year":"2002","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341964086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341964086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/4\/574\/407332\/mdg150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:13:56Z","timestamp":1582251236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341964086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["S092375341964086X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg150","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}